Cardiovascular outcome studies Although multiple clinical trials evaluating cardiovascular events associated with GLP-1 RA use as the primary outcome are currently ongoing (Table 1), abundant non-primary outcome data are available from many clinical trials on the efficacy of GLP-1 RAs marketed earlier, such as exenatide (DURATION studies) and liraglutide (LEAD studies)
GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) Gastrointestinal side effects dominate this class
Oxoneg effervescent tablet offers antioxidant support, promotes detoxification, enhances skin health, and may improve well-being
Research shows that fat found in the abdomen and flanks responds better to treatment than the type of fat that shows up in areas like thighs
for others a health scare or a blood test, or the concern of a loved one might be
doi: 10.1136/bmj.304.6833.1010 442 CleareAJBearnJAllainTMcGregorAWesselySMurrayRMet al